Star Combo Pharma (ASX: S66) — Perfil da empresa, notícias e dados financeiros
Star Combo Pharma is a manufacturer and distributor of nutritional products, dietary supplements, and skincare formulations based in Australia.
Star Combo Pharma
Star Combo Pharma is a manufacturer and distributor of nutritional products, dietary supplements, and skincare formulations based in Australia. The company develops, produces, and commercializes proprietary health brands, including Costar, Living Healthy, Amax, and J&K, serving domestic and international markets primarily in China and Asia. Operating a Therapeutic Goods Administration licensed manufacturing facility in Smithfield, New South Wales, the business offers contract manufacturing and original equipment manufacturer services across various formats such as capsules, liquids, and powders. It also engages in research and advanced manufacturing partnerships to develop proprietary health ingredients.
Resumo
Operações
Produtos e/ou serviços de Star Combo Pharma
- Contract OEM Manufacturing: Contract manufacturing services for vitamins, dietary supplements, and health products, operating out of a Therapeutic Goods Administration licensed facility to produce soft gel capsules, hard capsules, powders, and liquid formulations for global clients.
- Costar Health Supplements: Line of nutritional and health supplement products, including specialized formulations such as NMN capsules, spirulina tablets, and cranberry capsules distributed across domestic retail channels and Asian export markets.
- Living Healthy Products: Branded vitamin and mineral supplement range tailored for daily wellness and health maintenance, supplied to retail pharmacy networks, health food outlets, and e-commerce distribution platforms.
- Amax Nutritional Supplements: Range of natural health and complementary wellness products designed for preventive healthcare, targeting consumer markets across Australia and international export destinations in North Asia.
- J&K Skincare Solutions: Formulated skincare and cosmetic products including sheep placenta collagen liquids, anti-wrinkle eye gels, hyaluronic acid face masks, and skin Q10 serums distributed across domestic and international skincare markets.
- Ingredient Development & Research: Research and advanced manufacturing operations focused on developing proprietary functional ingredients, including TGA-approved formulations such as InuFructis, alongside university partnerships for intelligent manufacturing technologies.
equipe executiva do Star Combo Pharma
- Su ZhangCEO & Executive Director
- JinXing ZhangFounder, MD & Director
- James NiChief Financial Officer
- He BenChief Operating Officer
- Patrick James RaperCompany Secretary
Histórico de dividendos
Dividendos por ação pagos pela Star Combo Pharma, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | A$0.0030 | — | — | A$0.0030 |
| FY2026 | A$0.0037 | — | — | A$0.0037 |
| FY2025 | A$0.0037 | — | — | A$0.0037 |
Principais indicadores financeiros
Resultados divulgados pela Star Combo Pharma.
- Cap. de mercado
- 18,9 mi
- Receita (TTM)
- 23,6 mi
- P/L
- —
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- 2.1%
- Margem de lucro
- 1.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 23,6 mi | -231,1 mil | 394,6 mil | |
| 27,8 mi | -238 mil | 5,2 mi | |
| 26 mi | 723,4 mil | 747,3 mil | |
| 24,7 mi | 961,8 mil | -4 mi |